Home › Companies › BRIDGEBIO PHARMA INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and BRIDGEBIO PHARMA INC.’s Form 8-K, filed June 24, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 21, 2024: 8 items on BRIDGEBIO PHARMA INC.’s Form 8-K, filed June 24, 2024: 3 approved · 5 passed (calculated).
Significant dissent: 1 director (26.0% against).
Notable dissent: 1 equity or compensation plan (17.4% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore BRIDGEBIO PHARMA INC. in the interactive database Compare manager voting policies
These tallies are BRIDGEBIO PHARMA INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 24, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Eric Aguiar, M.D. | 139,080,658 | -- | -- | 4,552,096 | 17,266,449 | 97% | Passed (calculated) | — |
| Elect Director: Jennifer E. Cook | 139,063,404 | -- | -- | 4,569,350 | 17,266,449 | 97% | Passed (calculated) | — |
| Elect Director: Andrea J. Ellis | 139,229,888 | -- | -- | 4,402,866 | 17,266,449 | 97% | Passed (calculated) | — |
| Elect Director: Fred Hassan | 137,076,192 | -- | -- | 6,556,562 | 17,266,449 | 95% | Passed (calculated) | — |
| Elect Director: Ali J. Satvat | 106,237,448 | -- | -- | 37,395,306 | 17,266,449 | 74% | Passed (calculated) | — |
| 2. Non-binding Advisory Vote on Compensation of Named Executive Officers | 134,309,832 | 9,254,636 | 68,286 | -- | 17,266,449 | 94% | Approved | — |
| 3. Ratification of Appointment of Independent Registered Accounting Firm | 160,661,642 | 196,629 | 40,932 | -- | -- | 99.9% | Approved | — |
| 4. Approval of an Amendment and Restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan | 118,318,376 | 25,003,526 | 310,852 | -- | 17,266,449 | 83% | Approved | — |
Source: BRIDGEBIO PHARMA INC., Form 8-K, filed with the SEC on June 24, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
289 asset managers disclosed a vote on at least one BRIDGEBIO PHARMA INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 6 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal: Eric Aguiar, M.D.
BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Eric Aguiar, M.D.”): 139,080,658 for, 4,552,096 withheld, per its Form 8-K filed June 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 90 asset managers below reported 37,770,710 for, 2,412,317 withheld, 303,991 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 13,498,499 | 0 | 0 | 0 | For |
| Fidelity | 4,776,117 | 0 | 0 | 36,680 | For |
| BlackRock | 3,568,991 | 0 | 0 | 0 | For |
| State Street | 2,653,842 | 0 | 0 | 284 | For |
| T. Rowe Price | 1,576,723 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,144,213 | 0 | 0 | 0 | For |
| Invesco | 1,069,516 | 0 | 0 | 0 | For |
| Charles Schwab | 1,052,317 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 0 | 996,947 | Withhold |
| Lord Abbett | 921,378 | 0 | 0 | 0 | For |
| Principal | 345,388 | 0 | 0 | 403,425 | Mixed |
| American Century | 684,204 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 674,110 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 630,030 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 579,414 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 559,061 | Withhold |
| Equitable | 179,376 | 0 | 0 | 331,627 | Mixed |
| Capital Group | 413,794 | 0 | 0 | 0 | For |
| Victory Capital | 384,540 | 0 | 0 | 0 | For |
| MFS | 376,756 | 0 | 0 | 0 | For |
| TIAA | 303,278 | 0 | 0 | 0 | For |
| Jackson National | 264,398 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 0 | 0 | 242,995 | 0 | Abstain |
| Direxion Shares ETF Trust | 214,737 | 0 | 0 | 0 | For |
| Hartford | 202,784 | 0 | 0 | 0 | For |
Showing the 25 largest of 90 asset managers. All 90 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
74% Majority: yes · of votes cast
Description as filed by funds: To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal: Ali J. Satvat
BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Ali J. Satvat”): 106,237,448 for, 37,395,306 withheld, per its Form 8-K filed June 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 89 asset managers below reported 23,958,343 for, 144 against, 15,167,505 withheld, 781,612 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 13,498,499 | 0 | 0 | 0 | For |
| Fidelity | 4,723,513 | 0 | 0 | 89,284 | For |
| BlackRock | 0 | 0 | 0 | 3,568,991 | Withhold |
| State Street | 2,742 | 0 | 0 | 2,651,384 | Withhold |
| T. Rowe Price | 1,576,723 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 709,678 | 0 | 0 | 434,535 | Mixed |
| Invesco | 0 | 0 | 0 | 1,069,516 | Withhold |
| Charles Schwab | 1,052,317 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 0 | 996,947 | Withhold |
| Lord Abbett | 0 | 0 | 0 | 921,378 | Withhold |
| Principal | 0 | 0 | 0 | 748,813 | Withhold |
| American Century | 0 | 0 | 0 | 684,204 | Withhold |
| NEW ECONOMY FUND | 674,110 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 630,030 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 559,061 | Withhold |
| Equitable | 0 | 0 | 0 | 511,003 | Withhold |
| Capital Group | 413,794 | 0 | 0 | 0 | For |
| Victory Capital | 994 | 0 | 0 | 383,546 | Withhold |
| MFS | 0 | 0 | 0 | 376,756 | Withhold |
| TIAA | 0 | 0 | 0 | 303,278 | Withhold |
| Jackson National | 93,551 | 0 | 170,847 | 0 | Mixed |
| FINANCIAL INVESTORS TRUST | 0 | 0 | 242,995 | 0 | Abstain |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 214,737 | Withhold |
| Hartford | 202,784 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 0 | 0 | 150,858 | 0 | Abstain |
Showing the 25 largest of 89 asset managers. All 89 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal: Andrea J. Ellis
BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Andrea J. Ellis”): 139,229,888 for, 4,402,866 withheld, per its Form 8-K filed June 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 89 asset managers below reported 37,191,296 for, 2,412,317 withheld, 303,991 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 13,498,499 | 0 | 0 | 0 | For |
| Fidelity | 4,776,117 | 0 | 0 | 36,680 | For |
| BlackRock | 3,568,991 | 0 | 0 | 0 | For |
| State Street | 2,653,842 | 0 | 0 | 284 | For |
| T. Rowe Price | 1,576,723 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,144,213 | 0 | 0 | 0 | For |
| Invesco | 1,069,516 | 0 | 0 | 0 | For |
| Charles Schwab | 1,052,317 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 0 | 996,947 | Withhold |
| Lord Abbett | 921,378 | 0 | 0 | 0 | For |
| Principal | 345,388 | 0 | 0 | 403,425 | Mixed |
| American Century | 684,204 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 674,110 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 630,030 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 559,061 | Withhold |
| Equitable | 179,376 | 0 | 0 | 331,627 | Mixed |
| Capital Group | 413,794 | 0 | 0 | 0 | For |
| Victory Capital | 384,540 | 0 | 0 | 0 | For |
| MFS | 376,756 | 0 | 0 | 0 | For |
| TIAA | 303,278 | 0 | 0 | 0 | For |
| Jackson National | 264,398 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 0 | 0 | 242,995 | 0 | Abstain |
| Direxion Shares ETF Trust | 214,737 | 0 | 0 | 0 | For |
| Hartford | 202,784 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 150,858 | 0 | 0 | 0 | For |
Showing the 25 largest of 89 asset managers. All 89 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal: Fred Hassan
BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Fred Hassan”): 137,076,192 for, 6,556,562 withheld, per its Form 8-K filed June 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 89 asset managers below reported 36,790,951 for, 2,794,216 withheld, 322,437 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 13,498,499 | 0 | 0 | 0 | For |
| Fidelity | 4,776,117 | 0 | 0 | 36,680 | For |
| BlackRock | 3,568,991 | 0 | 0 | 0 | For |
| State Street | 2,653,842 | 0 | 0 | 284 | For |
| T. Rowe Price | 1,576,723 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,144,213 | 0 | 0 | 0 | For |
| Invesco | 1,069,516 | 0 | 0 | 0 | For |
| Charles Schwab | 1,052,317 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 0 | 996,947 | Withhold |
| Lord Abbett | 921,378 | 0 | 0 | 0 | For |
| Principal | 345,388 | 0 | 0 | 403,425 | Mixed |
| American Century | 684,204 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 674,110 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 630,030 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 559,061 | Withhold |
| Equitable | 179,376 | 0 | 0 | 331,627 | Mixed |
| Capital Group | 413,794 | 0 | 0 | 0 | For |
| Victory Capital | 383,546 | 0 | 0 | 994 | For |
| MFS | 376,756 | 0 | 0 | 0 | For |
| TIAA | 303,278 | 0 | 0 | 0 | For |
| Jackson National | 264,398 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 0 | 0 | 242,995 | 0 | Abstain |
| Direxion Shares ETF Trust | 214,737 | 0 | 0 | 0 | For |
| Hartford | 0 | 0 | 0 | 202,784 | Withhold |
| Bridge Builder Trust | 150,858 | 0 | 0 | 0 | For |
Showing the 25 largest of 89 asset managers. All 89 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal: Jennifer E. Cook
BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Jennifer E. Cook”): 139,063,404 for, 4,569,350 withheld, per its Form 8-K filed June 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 89 asset managers below reported 37,191,296 for, 2,412,317 withheld, 303,991 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 13,498,499 | 0 | 0 | 0 | For |
| Fidelity | 4,776,117 | 0 | 0 | 36,680 | For |
| BlackRock | 3,568,991 | 0 | 0 | 0 | For |
| State Street | 2,653,842 | 0 | 0 | 284 | For |
| T. Rowe Price | 1,576,723 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,144,213 | 0 | 0 | 0 | For |
| Invesco | 1,069,516 | 0 | 0 | 0 | For |
| Charles Schwab | 1,052,317 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 0 | 996,947 | Withhold |
| Lord Abbett | 921,378 | 0 | 0 | 0 | For |
| Principal | 345,388 | 0 | 0 | 403,425 | Mixed |
| American Century | 684,204 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 674,110 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 630,030 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 559,061 | Withhold |
| Equitable | 179,376 | 0 | 0 | 331,627 | Mixed |
| Capital Group | 413,794 | 0 | 0 | 0 | For |
| Victory Capital | 384,540 | 0 | 0 | 0 | For |
| MFS | 376,756 | 0 | 0 | 0 | For |
| TIAA | 303,278 | 0 | 0 | 0 | For |
| Jackson National | 264,398 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 0 | 0 | 242,995 | 0 | Abstain |
| Direxion Shares ETF Trust | 214,737 | 0 | 0 | 0 | For |
| Hartford | 202,784 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 150,858 | 0 | 0 | 0 | For |
Showing the 25 largest of 89 asset managers. All 89 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
83% Approved · of votes cast
Description as filed by funds: To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan to, among other things, increase the number of shares of common stock reserved for issuance thereunder by 6,500,000 shares.
BRIDGEBIO PHARMA INC.’s own tally for this item (“4. Approval of an Amendment and Restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan”): 118,318,376 for, 25,003,526 against — passed, per its Form 8-K filed June 24, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 4 - Approval of an Amendment and Restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan The Company's stockholders approved the amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan (th…”
Support: 83% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 94 asset managers below reported 33,094,009 for, 7,547,526 against, 23,210 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 13,498,499 | 0 | 0 | 0 | For |
| Fidelity | 4,812,797 | 0 | 0 | 0 | For |
| BlackRock | 3,568,991 | 0 | 0 | 0 | For |
| State Street | 2,650,477 | 3,649 | 0 | 0 | For |
| T. Rowe Price | 983,540 | 593,183 | 0 | 0 | Mixed |
| JANUS INVESTMENT FUND | 709,678 | 434,535 | 0 | 0 | Mixed |
| Invesco | 1,069,516 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 1,052,317 | 0 | 0 | Against |
| AllianceBernstein | 996,947 | 0 | 0 | 0 | For |
| Lord Abbett | 0 | 921,378 | 0 | 0 | Against |
| Principal | 403,425 | 345,388 | 0 | 0 | Mixed |
| American Century | 0 | 684,204 | 0 | 0 | Against |
| NEW ECONOMY FUND | 674,110 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 630,030 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 579,414 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 559,061 | 0 | 0 | 0 | For |
| Equitable | 511,003 | 0 | 0 | 0 | For |
| Capital Group | 413,794 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 384,540 | 0 | 0 | Against |
| MFS | 0 | 376,756 | 0 | 0 | Against |
| TIAA | 0 | 303,278 | 0 | 0 | Against |
| Jackson National | 0 | 264,398 | 0 | 0 | Against |
| FINANCIAL INVESTORS TRUST | 242,995 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 214,737 | 0 | 0 | Against |
| Hartford | 0 | 202,784 | 0 | 0 | Against |
Showing the 25 largest of 94 asset managers. All 94 are in the interactive database (link above).
Combines 16 wordings of this item as funds reported it.
94% Approved · of votes cast
Prior year: 77.7% for (June 21, 2023 meeting) ▲ 15.9 pts
Description as filed by funds: To cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers.
BRIDGEBIO PHARMA INC.’s own tally for this item (“2. Non-binding Advisory Vote on Compensation of Named Executive Officers”): 134,309,832 for, 9,254,636 against — passed, per its Form 8-K filed June 24, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 13,498,499 | 0 | 0 | 0 | For |
| Fidelity | 4,776,117 | 36,680 | 0 | 0 | For |
| BlackRock | 3,568,991 | 0 | 0 | 0 | For |
| State Street | 2,653,505 | 621 | 0 | 0 | For |
| T. Rowe Price | 1,576,723 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,144,213 | 0 | 0 | 0 | For |
| Invesco | 0 | 1,069,516 | 0 | 0 | Against |
| Charles Schwab | 1,052,317 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 996,947 | 0 | 0 | Against |
| Lord Abbett | 921,378 | 0 | 0 | 0 | For |
| Principal | 543,013 | 205,800 | 0 | 0 | Mixed |
| American Century | 0 | 684,204 | 0 | 0 | Against |
| NEW ECONOMY FUND | 674,110 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 630,030 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 579,414 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 559,061 | 0 | 0 | Against |
| Equitable | 179,376 | 331,627 | 0 | 0 | Mixed |
| Capital Group | 413,794 | 0 | 0 | 0 | For |
| Victory Capital | 383,546 | 994 | 0 | 0 | For |
| MFS | 0 | 376,756 | 0 | 0 | Against |
| TIAA | 303,278 | 0 | 0 | 0 | For |
| Jackson National | 170,847 | 93,551 | 0 | 0 | Mixed |
| FINANCIAL INVESTORS TRUST | 242,995 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 214,737 | 0 | 0 | 0 | For |
| Hartford | 0 | 202,784 | 0 | 0 | Against |
Fund voting reports, all 90 managers: 35,190,420 for, 5,167,693 against, 23,210 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | 0 | 0 | 0 | For |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | 0 | 0 | 0 | For |
| Aisling Capital Management LP | 6,068,125 | 0 | 0 | 0 | For |
| State Street | 4,956,785 | 699 | 0 | 0 | For |
| Laurion Capital Management LP | 3,450,031 | 0 | 0 | 0 | For |
| BlackRock | 3,258,779 | 18,660 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,772,235 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 2,504,873 | 0 | 0 | Against |
| PICTET ASSET MANAGEMENT SA | 2,276,346 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,192,261 | 0 | 0 | 0 | For |
| Fidelity | 2,129,463 | 0 | 0 | 0 | For |
| Janus Henderson | 2,076,340 | 0 | 0 | 0 | For |
| SC US (TTGP), LTD. | 1,860,364 | 0 | 0 | 0 | For |
| HHLR ADVISORS, LTD. | 1,367,489 | 0 | 0 | 0 | For |
| Cormorant Asset Management, LP | 1,317,824 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 1,259,213 | 0 | 0 | 0 | For |
| Wellington | 0 | 1,253,589 | 0 | 0 | Against |
| Capital Research Global Investors | 1,111,975 | 0 | 0 | 0 | For |
| John Hancock | 1,093,323 | 0 | 0 | 0 | For |
| Charles Schwab | 1,081,534 | 0 | 0 | 0 | For |
| LORD, ABBETT & CO. LLC | 1,039,049 | 0 | 0 | 0 | For |
| PRIMECAP MANAGEMENT CO/CA/ | 927,230 | 0 | 0 | 0 | For |
| Invesco | 0 | 860,433 | 0 | 0 | Against |
| American Century | 0 | 746,283 | 0 | 0 | Against |
| Octagon Capital Advisors LP | 690,000 | 0 | 0 | 0 | For |
Institutional-manager reports, all 224 managers: 107,930,219 for, 8,044,484 against, 18 abstained. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Prior year: 100.0% for (June 21, 2023 meeting) ▼ 0.1 pts
Description as filed by funds: To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.
BRIDGEBIO PHARMA INC.’s own tally for this item (“3. Ratification of Appointment of Independent Registered Accounting Firm”): 160,661,642 for, 196,629 against — passed, per its Form 8-K filed June 24, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 90 asset managers below reported 40,358,053 for, 23,210 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 13,498,499 | 0 | 0 | 0 | For |
| Fidelity | 4,812,797 | 0 | 0 | 0 | For |
| BlackRock | 3,568,991 | 0 | 0 | 0 | For |
| State Street | 2,654,126 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,576,723 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,144,213 | 0 | 0 | 0 | For |
| Invesco | 1,069,516 | 0 | 0 | 0 | For |
| Charles Schwab | 1,052,317 | 0 | 0 | 0 | For |
| AllianceBernstein | 996,947 | 0 | 0 | 0 | For |
| Lord Abbett | 921,378 | 0 | 0 | 0 | For |
| Principal | 748,813 | 0 | 0 | 0 | For |
| American Century | 684,204 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 674,110 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 630,030 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 579,414 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 559,061 | 0 | 0 | 0 | For |
| Equitable | 511,003 | 0 | 0 | 0 | For |
| Capital Group | 413,794 | 0 | 0 | 0 | For |
| Victory Capital | 384,540 | 0 | 0 | 0 | For |
| MFS | 376,756 | 0 | 0 | 0 | For |
| TIAA | 303,278 | 0 | 0 | 0 | For |
| Jackson National | 264,398 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 242,995 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 214,737 | 0 | 0 | 0 | For |
| Hartford | 202,784 | 0 | 0 | 0 | For |
Showing the 25 largest of 90 asset managers. All 90 are in the interactive database (link above).
Not shown here: this season’s fund filings also report 1 item from the meeting of June 20, 2025, which belongs to the 2024-2025 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 187,122,744 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 7.21% |
| 2 | Fidelity | 2.57% |
| 3 | BlackRock | 1.91% |
| 4 | State Street | 1.42% |
| 5 | T. Rowe Price | 0.84% |
| 6 | JANUS INVESTMENT FUND | 0.61% |
| 7 | Invesco | 0.57% |
| 8 | Charles Schwab | 0.56% |
| 9 | AllianceBernstein | 0.53% |
| 10 | Lord Abbett | 0.49% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Kohlberg Kravis Roberts & Co. L.P. | 16.60% |
| 2 | VIKING GLOBAL INVESTORS LP | 13.42% |
| 3 | Aisling Capital Management LP | 3.24% |
| 4 | State Street | 2.65% |
| 5 | Laurion Capital Management LP | 1.84% |
| 6 | BlackRock | 1.75% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 1.48% |
| 8 | AllianceBernstein | 1.34% |
| 9 | PICTET ASSET MANAGEMENT SA | 1.22% |
| 10 | T. Rowe Price | 1.17% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Ali J. Satvat | 31,476,578 | 16.82% | Proxy statement (DEF 14A), table as of April 1, 2024 |
| KKR Genetic Disorder L.P. | 31,060,971 | 16.60% | Proxy statement (DEF 14A), table as of April 1, 2024 |
| Viking Global Entities | 25,120,991 | 13.42% | Proxy statement (DEF 14A), table as of April 1, 2024 |
| Vanguard Group | 16,832,059 | 9.00% | Form 13F, quarter ended March 31, 2024 |
| BlackRock | 14,411,203 | 7.70% | Form 13F, quarter ended March 31, 2024 |
| Neil Kumar, Ph.D. | 10,114,271 | 5.41% | Proxy statement (DEF 14A), table as of April 1, 2024 |
| State Street | 5,392,862 | 2.88% | Form 13F, quarter ended March 31, 2024 |
| Geode Capital | 2,862,845 | 1.53% | Form 13F, quarter ended March 31, 2024 |
| Goldman Sachs | 2,313,759 | 1.24% | Form 13F, quarter ended March 31, 2024 |
| Charles Homcy, M.D. | 1,801,506 | 0.96% | Proxy statement (DEF 14A), table as of April 1, 2024 |
Percentages above are of 187,122,744 shares outstanding, as reported by BRIDGEBIO PHARMA INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At BRIDGEBIO PHARMA INC.'s shareholder meeting held June 21, 2024, in the 2023-2024 proxy season, 289 asset managers reported votes on at least one of its 8 ballot items in their SEC Form N-PX filings, covering 2,630 separate fund positions. On the most widely held item on that ballot — To cast a non-binding, advisory vote to approve the compensation of the Company's named… — BRIDGEBIO PHARMA INC.'s filing reports the proposal as approved, with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: BRIDGEBIO PHARMA INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 24, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BRIDGEBIO PHARMA INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
BRIDGEBIO PHARMA INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “BRIDGEBIO PHARMA (BBIO) 2024 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/bridgebio-pharma-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.